Cargando…

Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study

Background and Purpose: Apatinib is a novel antiangiogenic agent that can target vascular endothelial cell growth factor 2. The aim of our study was to evaluate the efficacy and safety of apatinib mesylate in the treatment of advanced hepatocellular carcinoma (HCC) in the real world. Methods: We ret...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Zhuangzhuang, Liu, Zijing, Zhang, Haifeng, Guo, Xiao, Jia, Xiaojing, Wang, Jianfeng, Meng, Lingbin, Xin, Ying, Jiang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152289/
https://www.ncbi.nlm.nih.gov/pubmed/35656302
http://dx.doi.org/10.3389/fphar.2022.894016
_version_ 1784717614821408768
author Zheng, Zhuangzhuang
Liu, Zijing
Zhang, Haifeng
Guo, Xiao
Jia, Xiaojing
Wang, Jianfeng
Meng, Lingbin
Xin, Ying
Jiang, Xin
author_facet Zheng, Zhuangzhuang
Liu, Zijing
Zhang, Haifeng
Guo, Xiao
Jia, Xiaojing
Wang, Jianfeng
Meng, Lingbin
Xin, Ying
Jiang, Xin
author_sort Zheng, Zhuangzhuang
collection PubMed
description Background and Purpose: Apatinib is a novel antiangiogenic agent that can target vascular endothelial cell growth factor 2. The aim of our study was to evaluate the efficacy and safety of apatinib mesylate in the treatment of advanced hepatocellular carcinoma (HCC) in the real world. Methods: We retrospectively analyzed 178 patients with advanced HCC who had been treated with apatinib mesylate from January 2017 to March 2020. The primary outcome indexes were progression-free survival (PFS) and overall survival (OS), and the secondary outcome indexes were overall response rate (ORR), disease control rate (DCR), and incidence of treatment-related adverse reactions. Results: Univariate analysis showed that patients with third-line treatment (p <0.001), alpha fetoprotein (AFP) ≥400 ng/ml (p <0.05), distant metastasis (p <0.05), portal vein tumor thrombus (PVTT) (p <0.05), and apatinib monotherapy (p <0.001) had shorter survival. Multivariate analysis confirmed that third-line drugs, PVTT, and combination therapy were independent prognostic factors for PFS in all patients. Univariate analysis showed that Eastern Cooperative Oncology Group (ECOG) scores (p <0.05), line of apatinib (p <0.001), AFP (p <0.001), tumor progression (p <0.05), PVTT (p <0.05), and combination therapy (p <0.001) may impact the OS. Multivariate analysis proved that AFP, PVTT, and combination therapy were independent prognostic factors for OS. The most common adverse reactions were secondary hypertension (29.21%), symptoms of fatigue (16.85%), hand and foot syndrome (16.29%), vomiting (14.04%), liver dysfunction (6.18%), and proteinuria (6.74%). Most of the adverse reactions were Grade 1 or 2. Conclusion: Apatinib mesylate is an effective treatment for advanced HCC, and its adverse reactions are relatively mild. Line of apatinib, PVTT, AFP level, and combination therapy were independent prognostic factors for patients with advanced HCC who were treated with apatinib.
format Online
Article
Text
id pubmed-9152289
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91522892022-06-01 Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study Zheng, Zhuangzhuang Liu, Zijing Zhang, Haifeng Guo, Xiao Jia, Xiaojing Wang, Jianfeng Meng, Lingbin Xin, Ying Jiang, Xin Front Pharmacol Pharmacology Background and Purpose: Apatinib is a novel antiangiogenic agent that can target vascular endothelial cell growth factor 2. The aim of our study was to evaluate the efficacy and safety of apatinib mesylate in the treatment of advanced hepatocellular carcinoma (HCC) in the real world. Methods: We retrospectively analyzed 178 patients with advanced HCC who had been treated with apatinib mesylate from January 2017 to March 2020. The primary outcome indexes were progression-free survival (PFS) and overall survival (OS), and the secondary outcome indexes were overall response rate (ORR), disease control rate (DCR), and incidence of treatment-related adverse reactions. Results: Univariate analysis showed that patients with third-line treatment (p <0.001), alpha fetoprotein (AFP) ≥400 ng/ml (p <0.05), distant metastasis (p <0.05), portal vein tumor thrombus (PVTT) (p <0.05), and apatinib monotherapy (p <0.001) had shorter survival. Multivariate analysis confirmed that third-line drugs, PVTT, and combination therapy were independent prognostic factors for PFS in all patients. Univariate analysis showed that Eastern Cooperative Oncology Group (ECOG) scores (p <0.05), line of apatinib (p <0.001), AFP (p <0.001), tumor progression (p <0.05), PVTT (p <0.05), and combination therapy (p <0.001) may impact the OS. Multivariate analysis proved that AFP, PVTT, and combination therapy were independent prognostic factors for OS. The most common adverse reactions were secondary hypertension (29.21%), symptoms of fatigue (16.85%), hand and foot syndrome (16.29%), vomiting (14.04%), liver dysfunction (6.18%), and proteinuria (6.74%). Most of the adverse reactions were Grade 1 or 2. Conclusion: Apatinib mesylate is an effective treatment for advanced HCC, and its adverse reactions are relatively mild. Line of apatinib, PVTT, AFP level, and combination therapy were independent prognostic factors for patients with advanced HCC who were treated with apatinib. Frontiers Media S.A. 2022-05-17 /pmc/articles/PMC9152289/ /pubmed/35656302 http://dx.doi.org/10.3389/fphar.2022.894016 Text en Copyright © 2022 Zheng, Liu, Zhang, Guo, Jia, Wang, Meng, Xin and Jiang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zheng, Zhuangzhuang
Liu, Zijing
Zhang, Haifeng
Guo, Xiao
Jia, Xiaojing
Wang, Jianfeng
Meng, Lingbin
Xin, Ying
Jiang, Xin
Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study
title Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study
title_full Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study
title_fullStr Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study
title_full_unstemmed Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study
title_short Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study
title_sort efficacy and safety of apatinib in advanced hepatocellular carcinoma: a multicenter real world retrospective study
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152289/
https://www.ncbi.nlm.nih.gov/pubmed/35656302
http://dx.doi.org/10.3389/fphar.2022.894016
work_keys_str_mv AT zhengzhuangzhuang efficacyandsafetyofapatinibinadvancedhepatocellularcarcinomaamulticenterrealworldretrospectivestudy
AT liuzijing efficacyandsafetyofapatinibinadvancedhepatocellularcarcinomaamulticenterrealworldretrospectivestudy
AT zhanghaifeng efficacyandsafetyofapatinibinadvancedhepatocellularcarcinomaamulticenterrealworldretrospectivestudy
AT guoxiao efficacyandsafetyofapatinibinadvancedhepatocellularcarcinomaamulticenterrealworldretrospectivestudy
AT jiaxiaojing efficacyandsafetyofapatinibinadvancedhepatocellularcarcinomaamulticenterrealworldretrospectivestudy
AT wangjianfeng efficacyandsafetyofapatinibinadvancedhepatocellularcarcinomaamulticenterrealworldretrospectivestudy
AT menglingbin efficacyandsafetyofapatinibinadvancedhepatocellularcarcinomaamulticenterrealworldretrospectivestudy
AT xinying efficacyandsafetyofapatinibinadvancedhepatocellularcarcinomaamulticenterrealworldretrospectivestudy
AT jiangxin efficacyandsafetyofapatinibinadvancedhepatocellularcarcinomaamulticenterrealworldretrospectivestudy